Filed pursuant to Rule 433 of the Securities Act of 1933

Issuer Free Writing Prospectus dated January 20, 2022

Relating to the Preliminary Prospectus dated January 6, 2022

Registration Statement File No. 333-260137

This free writing prospectus relates to the proposed public offering of shares of common stock, par value $0.00001 per share, and warrants of Blue Water Vaccines, Inc. (the “Company”) which are being registered on a Registration Statement on Form S-1, as amended (File No. 333-260137) (the “Registration Statement”). This free writing prospectus should be read together with the preliminary prospectus dated January 6, 2022 included in that Registration Statement which can be accessed through the following link:

https://www.sec.gov/Archives/edgar/data/0001782107/000121390022000991/fs12022a5_bluewatervac.htm

The Company has filed the Registration Statement (including a prospectus) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus in that Registration Statement (including the Risk Factors contained therein) and other documents that the Company has filed with the SEC for more complete information about our company and this offering. You may get these documents for free by visiting EDGAR or the SEC web site at www.sec.gov. Alternatively, the Company, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it from Maxim Group LLC, 300 Park Avenue, 16th Floor, New York NY 10022 by calling 212-895-3745.

Corporate Overview ` Developing Transformational Vaccines 1

Disclaimer The Presentation (the “Presentation”) has been prepared by Blue Water Vaccines, Inc. (the "Company"). Certain information contained herein has been derived from sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, the Company makes no representation or warranty with respect to the accuracy of such information. This Presentation does not purport to contain all of the information that may be required to evaluate a possible transaction. The Company has filed a registration statement on Form S - 1, as amended (Registration No. 333 - 260137) with the Securities and Exchange Commission (“SEC”). The offering to which this Presentation will be made is pursuant to a prospectus included in the registration statement after the registration statement has been declared effective by the SEC. Before you invest, you should read the registration statement and the related prospectus and the other documents that we have filed with the SEC for more complete information about us and the offering. You may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov . This Presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Company in any jurisdiction, domestic of foreign, where the offer, solicitation or sale is not permitted or would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities of the Company have not been registered under the Securities Act or any other applicable securities law. The Company's securities have not been approved or disapproved by the SEC or any other regulatory or governmental authority, nor have any of the foregoing passed upon the accuracy or adequacy of the information presented. Any representation to the contrary is a criminal offense . Statements contained in this Presentation relate to the historical experience of the Company’s founders, officers, directors or their affiliates. An investment in the Company is not an investment in any of their past investments, companies or funds affiliated with them. The historical results of these investments, companies or funds is not necessarily indicative of future performance of the Company. 2

Forward - Looking Statements This Presentation and any accompanying oral presentation contains forward - looking statements within the meaning of federal securities law and are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary. These forward - looking statements appear in a number of places throughout this Presentation and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things; our ongoing and planned product development; the timing of, and our ability to make, regulatory filings and obtain and maintain regulatory approvals for our product candidates, as applicable; our intellectual property position; the degree of clinical utility of our products; our ability to develop commercial functions; our results of operations; cash needs; financial condition, liquidity, prospects, growth and strategies; the industry in which we operate; and the trends tha t may affect the industry or us . We may, in some cases, use terms such as “believes,” “estimates,” “anticipates,” “expects,” “predicts,” “plans,” “intends,” “possible,” “potential,” “may,” “could,” “might,” “will,” “should,” “would,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward - looking statements. Although we believe that we have a reasonable basis for each forward - looking statement contained in this Presentation, we caution you that forward - looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward - looking statements contained in this Presentation . You should also read carefully the factors described in the “Risk Factors” section and other parts of any prospectus that is distributed in order to better understand the risks and uncertainties inherent in our business and underlying any forward - looking statements. As a result of these factors, we cannot assure you that the forward - looking statements in this Presentation will prove to be accurate. Furthermore, if our forward - looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward - looking statements, you should not regard these statements as a representation or warranty by any person that we will achieve our objectives and plans in any specified timeframe, or at all. Any forward - looking statements that we make in this Presentation speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this Presentation or to reflect the occurrence of unanticipated events. 3

Joseph Hernandez Founder, Chairman & Chief Executive Officer • Founder, Chairman, Blue Water Acquisition Corporation, (now Clarus, CRXT); Founder, Chairman Noachis Terra, Inc. (Oragenics, Inc) • M.Sc., Chronic Disease Epidemiology Student, Yale; MBA, University of Florida Erin Henderson Chief Business Officer Ronald Cobb, Ph.D. Head of Science and Discovery • Vaccine development expertise • Former CSO, Ology Bioservices • Ph.D , Biochemistry, Medical College of Georgia Jon Garfield Chief Financial Officer • Financial and M&A expertise • Prior big four accounting firm experience • B.B.A, Accounting, University of Texas at Austin Andrew Skibo Head Biologic Operations • Biological Manufacturing expertise • Former, EVP, Operations, AstraZeneca/ MedImmune • M.S., Chemical Engineering, Massachusetts Institute of Technology 4 • Administrative, corporate and stakeholder relations expertise • Former Managing Principal, The Aetos Group • B.S., Chemical Engineering, Auburn University Led by experienced entrepreneurs who bring sustained records of successfully leading innovation and commercialization Accomplished Management Team and Board of Directors Post IPO Board of Directors Michael Venerable CEO, CincyTech Allan Shaw CFO, Portage Biotech Inc. (NASDAQ: PRTG) Kimberly Murphy Board of Directors at Oragenics , Inc (NYSE: OGEN) and Blue Water Acquisition Corp. (NASDAQ: BLUW) James Sapirstein President & CEO, AzurRx Biopharma (NASDAQ: AZRX)

5 Partnered with Renowned Leaders Ming Tan, Ph.D. Co - Inventor, S & P Particle VLP Platform, Norovirus - Rotavirus vaccine Assistant Professor, University of Cincinnati, Department of Pediatrics Xi Jason Jiang, Ph.D. Co - Inventor, S & P Particle VLP Platform, Norovirus - Rotavirus vaccine Professor, University of Cincinnati, Department of Pediatrics Jason Rosch, Ph.D. Inventor, S. pneumoniae vaccine Associate Member, St. Jude Faculty Sunetra Gupta, Ph.D. Co - Inventor, Universal Influenza vaccine Department of Zoology, University of Oxford . Post IPO Scientific Advisory Board Sunetra Gupta, Ph.D. Professor, University of Oxford C. David Zarley, Ph.D. Vaccine Development, Vice President., (Retired), Pfizer, Inc. John Rice, Ph.D. Life Sciences Managing Director, CincyTech

6 Investment Highlights ? Lead Vaccine Candidates: Targeting Universal and H1 Influenza utilizing proprietary influenza epitopes of limited variability (ELV) that remain present through viral mutation Esteemed Collaborators: University of Oxford, Cincinnati Children’s, St. Jude’s Children’s POC: Proof - of - Concept IND: Investigational New Drug Application. AOM: acute otitis media ? Opportunistic Business model : Exclusive licenses of assets and platforms, broad business development, opportunistic growth and expansion Broad and diverse vaccine pipeline: Novel preclinical vaccine candidates with near - term POC and IND Proprietary Versatile Vaccine Platform: POC, multi - valent, scalable, and flexible discovery engine with broad therapeutic capabilities We improve the lives of people through discovery and development of novel, transformational and preventive vaccines AOM Prevention Candidate: Targeting S. pneumoniae utilizing a proprietary live - attenuated strain with intranasal delivery

7 Next - Generation Novel Vaccine Pipeline Infectious Disease Program Candidate Preclinical Phase 1 Phase 2 Phase 3 Licensee *Status Universal Flu BWV - 101 1H22: pre - clinical POC H1 pre - pandemic BWV - 102 1H22: start IND enabling studies S. pneumo induced AOM (intranasal) BWV - 201 1H22 : start IND enabling studies Norovirus / Rotavirus BWV - 301 1H22: pre - clinical POC Norovirus / Malaria BWV - 302 2H22 : start IND enabling studies * Pipeline projections are based upon the completion of the initial public offering.

8 POC: animal models showed strong enhanced immunogenicity Our novel Shell and Protrusion (S&P) norovirus platform combines 2 or more immunogenic components: a norovirus antigen + at least one additional antigen = novel vaccines Our Novel Vaccine Platform 1 Discovery Engine: stable, flexible, cost - effective nanoparticles Broad therapeutic capabilities & Partnering opportunities 1. Tan et al. Journ . Virology 2011

Our Vaccine Candidates 9

BWV - 101: Universal Flu BWV - 102: H1 Aiming to eradicate the flu, universally, with a smart vaccine that targets frequently occurring virulent epitopes. 10

Overview 3 12 Worldwide estimates each year: • 1 billion cases of influenza infection • 3 - 5 million severe cases • 290,000 - 650,000 deaths • $4 billion is spent annually on influenza vaccines worldwide • $87 billion estimated lost productivity in the US alone Economic Impact 4 Current Treatment limitations 5 • Target regions of the virus that is highly variable • Annual flu vaccine effectiveness at preventing disease ranges between 20 and 60% • Updated annually and reformulated 6 - months prior to flu season and may not protect against subsequent strains Our mission is grounded in the belief that vaccines are the best way to protect against the flu Influenza 3. https:// www.who.int /influenza/Global 4. https:// www.reportlinker.com 5. cdc.gov

12 Influenza Viruses 6 Influenza A: epidemic and pandemic Influenza B: epidemic, slower mutations Influenza C: mild, non - pandemic, vaccine not needed Influenza D: animals only Subtypes based on two viral proteins: H: hemagglutinin (HA) N: neuraminidase Lineages B: Victoria B: Yamagata Influenza A&B cause most of human illness and the flu season 18 different hemagglutinin subtypes (H1 - H18) 11 different neuraminidase subtypes (N1 - N11) 6. https:// www.cdc.gov /flu/about/viruses/ types.htm

13 Our Approach Our vaccine overcomes such issues by targeting regions, or epitopes, of the virus which are of limited variability. These epitopes remain present through the virus mutations. By identifying multiple epitopes of limited variability, it is possible to produce vaccines or a single vaccine to protect against all previous and future H1 flu strains. Target regions that are highly immunogenic of high variability or evolve frequently. These vaccines need to be updated regularly and administered annually. Current influenza vaccine can be divided into two groups: Global head domain (variable) Stem / Stalk domain (conserved region) hemagglutinin Target regions that are conserved with low immunogenicity. There is less need for updating these vaccines, but they provide a poor immune response.

14 Proprietary Epitopes of Limited Variability (ELVs) 7 • Antigen/epitope evolution is limited in certain regions of the influenza virus • ELVs are naturally immunogenic – Drive antigenic evolution which could result in a pandemic – Cycle between limited number of different conformations • We licensed IP for cross - protective epitopes for our vaccine candidates: – Developed at the University of Oxford by Dr. Sunetra Gupta – Mathematical research has pinpointed ELVs that provide immunity to multiple strains – Identified ELVsin historical H1, H3 influenza and influenza B strains 7. Thompson et al. Nature Communications. 2018. 9:385

15 ELV vaccine Proof - of - concept 7 Vaccination of mice with epitopes from H1N1 influenza viruses circulating in 2006 and 1977 provided protection against a strain that last circulated in 1934 Data demonstrate H1N1 ELVs provide cross - reactive immune response in historical influenza strains 7. Thompson et al. Nature Communications. 2018. 9:385

16 ELV vaccine Proof - of - concept 7 Influenza challenge • Data in mice models demonstrated that vaccinated mice did not have as severe of a reduction in weight loss compared to the control groups • Survival curves demonstrated that vaccinated mice were able to produce antibodies to protect against historical flu strains 7. Thompson et al. Nature Communications. 2018. 9:385

17 Our Influenza Vaccine Program 7 • BWV - 101: – Identified naturally immunogenic epitopes for H1, H3 and influenza B. – Continued discovery and optimization of H3 and Influenza B epitopes – Exploring S 60 and P 24 Presentation of ELVs . • BWV - 102: – To address potential pandemic zoonotic H1 strains, specifically the G4 EA H1N1 identified by scientists and reported on in June 2020, as the potential next pandemic strain. [2] – Broad cross - reactive antibodies in other strains such as H10N3 (bird flu), and pandemic strains including H5NX, H7NX, and H9NX. – Therefore, we foresee the development of H1N1 vaccine as a priority due to its high cross - reactive priorities Using our proprietary computational approach, we are able to optimize the design of the domains. VLP Presentation assessments are targeted for the first half of 2022 7. Thompson et al. Nature Communications. 2018. 9:385 [2]Sun et al. PNAS June 2020

BWV - 201: S. Pneumoniae induced acute otitis media (AOM) Blue Water Vaccines is committed to alleviating pain in children who suffer from S. pneumoniae induced middle ear infections. 18

Overview 19 Worldwide estimates each year: • 709 million cases per year, with 51% occurring in children under 5 years old 8,10 • By 3 years of age, 80% of children are expected to have at least one episode 8 • AOM due to S. pneumoniae is estimated to be 30 - 50% 9 • $4.3 billion USD is spent on AOM treatment each year in the U.S. alone 10 Impact Current Treatment limitations • Current treatment for AOM is by antibiotic prescription, with more than 80% of all consultations resulting in a prescription 10 • Even with introduction of the Prevnar13 in 2010, 26 - 36% of cases of AOM in U.S. were caused by S. pneumoniae 10 Current treatments have limited effect on prevention of AOM due to S. pneumoniae 10 S. pneumo induced AOM 8. Monsata 2012 2012; 7(4): e36226 , 9. Dagan et al. The Journal of Infectious Diseases , Volume 181, Issue 4, April 2000 , 10. Tong et al BMC Health Serv Res. 2018; 18: 318.

20 Our Approach • In - licensed the ଉ novel attenuated ଉ S. pneumoniae strain ଉ from ଉ St. Jude Children’s Research Hospital • Our BWV - 201 vaccine ଉ candidate is a ଉ live ଉ attenuated ଉ serotype - independent ଉ vaccine • Long - term preventive intranasal vaccine ଉ for ଉଉ S. pneumoniae ଉଉ induced acute otitis media (AOM) – Potential short - term pain and/or long - term harmful side effects – Complications from AOM include sensorineural hearing loss (SNHL) • Production of vaccine is straightforward – Utilizes the entire bacterium with ଉ purification and concentration steps only in the downstream process – Reduces the time and cost of production significantly compared to the commonly used vaccines

21 BWV - 201 Proof of Concept 11 Deletion of ftsY , a central component of the signal recognition particle (SRP) pathway show heightened sensitivity to environmental stress and have greatly diminished virulence. Deletion of caxP , a calcium/magnesium transporter, renders host physiological conditions in blood and mucosa toxic to the bacterium. Vaccines in Study Serotypes D39 D ftsY 2 D39 D caxP 2 BHN97D ftsY 19F BHN97 D caxP 19F PCV7 4, 6B, 9V, 14, 18C, 19A, 19F & 23 F PCV13 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F & 23 F PPV23 1, 3, 4,5, 6B, 7F, 8, 9V, 10A, 11A,12F, 14, 15, 17A 18C, 19A, 19F, 20, 22F, 23F & 33 F Mock None 11 Rosch, Jason W et al. “A live - attenuated pneumococcal vaccine elicits CD4+ T - cell dependent class switching and provides sero type independent protection against acute otitis media.” EMBO molecular medicine vol. 6,1 (2014): 141 - 54. doi:10.1002/emmm.201202150

22 Pre - Clinical Data: Mouse Model 11 Vaccine Protection against AOM and sinusitis • 25 - 31 per group, performed at least twice • Vaccinated with either Mock or live attenuated with deletions on either type 2 or 19 F background. • Challenged with bioluminescent BMH97X (type 19F), imaged twice daily for AOM and sinusitis A. The proportion of mice developing infection of ear or sinus by Xenogen imaging PPV23 was used as a negative control B.,C. Representative pictures from bioluminescent imaging with (B) AOM and (C) both AOM and sinusitis. D - I. Representative histopathology at 4x (top row) and 40x (bottom row) of (D,G) normal ear, (E,H) mouse with mild AOM and (F,I) marked AOM 11. Rosch, Jason W et al. “A live - attenuated pneumococcal vaccine elicits CD4+ T - cell dependent class switching and provides se rotype independent protection against acute otitis media.” EMBO molecular medicine vol. 6,1 (2014): 141 - 54. doi:10.1002/emmm.201202150

23 Pre - Clinical Data: Chinchilla Model 11 Vaccine protection in chinchilla model of AOM A. The BHN97 strain is capable of causing AOM in chinchillas via intranasal administration as observed by recoverable bacterial colony forming units (CFUs) from the middle ear (A) following challenge. B.,C. Following vaccination, a reduction in the number of culture positive ears in vaccinated group compared to the mock animals was observed (B) as well as significant reduction in recoverable CFUs from middle ear 7 days post challenge (C). 11. Rosch, Jason W et al. “A live - attenuated pneumococcal vaccine elicits CD4+ T - cell dependent class switching and provides ser otype independent protection against acute otitis media.” EMBO molecular medicine vol. 6,1 (2014): 141 - 54. doi:10.1002/emmm.201202150

x 24 Pre - Clinical Data: Mouse Model 11 • Mice were mock - vaccinated with PBS (Mock) or vaccinated with PCV13 or a live attenuated vaccine deleted for FtsY on a type 19F background (BNH97 D ftsY). A. Mice were challenged with a bioluminescent version of S. pneumoniae strain BNH54 (type 7F) and assessed by imaging for development of otitis media over 72 h (24 h time point is pictured). C. Weight loss observed in the animals further supported the observed protection. PCV13 contains type 7F antigen, so this was a homologous challenge for the PCV13 group but a heterologous challenge for the BNH97 D ftsY group. Vaccine protection against heterologous challenge 11. Rosch, Jason W et al. “A live - attenuated pneumococcal vaccine elicits CD4+ T - cell dependent class switching and provides se rotype independent protection against acute otitis media.” EMBO molecular medicine vol. 6,1 (2014): 141 - 54. doi:10.1002/emmm.201202150

BWV 301: Norovirus - Rotavirus We aim to mitigate the global abundance of pathogen mediated digestive tract infections via our novel norovirus/rotavirus chimeric vaccine. 25

S - domain 26 • Unique c apsid dual - domain proprieties: S&P • Stable, subviral nanoparticles • Scalable, flexible discovery engine • Multi - antigen and pathogen capabilities • Br oad therapeutical potential • Cost - effective and Rapid Production of Novel Vaccines • E.coli expression system S&P Platform Characteristics Versatile Vaccine Platform 1,2 • 60 freely exposed C - termini = S 60 nanoparticle • Foreign antigens fused to the end of the S domain via flexible linker • Uniform 60 - valent NoV VLPs via an expression system – never been produced before. • S 60 n nanoparticles maintained uniform complexity and size of vaccine particles P • 24 valent P nanoparticles= P 24 • Three loops = multi - antigen potential • Nanoparticles without adjuvant produce innate, humoral, and cellular immunity • inter - P domain disulfide bonds significantly stabilizes P 24 P - domain 1. TAN et al. REVIEW, Nanomedicine. 2012. 2. Xia et al. ACS Nano 2018 12 (11), 10665 - 10682. NoV : NoraVirus . VLP: Vector - like - Particle(s)

Overview 27 Worldwide estimates each year: Norovirus is the most common cause of acute gastroenteritis, 700 million cases. 12,14 • About 200 million cases are seen among children under 5 years old, leading to an estimated 50,000 child deaths every year. 12 Rotavirus causes an estimated 111 million episodes of diarrhea 12 • 2 million hospitalizations, and 352,000 – 592,000 deaths in children <5 years of age. 12 • Norovirus: $60.3 billion worldwide each year 13 Economic Impact Current Treatment limitations 12 • Norovirus: No vaccine is available • Rotavirus: Current vaccines exist. Two vaccines are authorized for use in infants in the U.S. with a reported efficacy of 85 - 95%. 15 Rotavirus is the most common cause of diarrheal disease among infants and young children 12 Norovirus - Rotavirus 12. cdc.gov / Parashar et al. EID Journ May 2003 13. Bartsch et al. PLoS One 2016; 11:e0151219. 14. Shah et al. Infect Dis Clin North Am. 2018 Mar; 32(1): 103 – 118. 15. https:// www.cdc.gov /vaccines/ vpd /rotavirus/hcp/about - vaccine.html

28 Pre - clinical Data: Gnotobiotic Pig Model 16 P 24 - VP8* vaccine protected against VirHRV diarrhea and reduced overall viral shedding. 16. Ramesh et al. Vaccines 2019, 7, 777 VirHRV = virulent human rotavirus

29 Vaccine provided neutralizing antibodies in serum collected from gnotobiotic pigs Pre - clinical Data: Gnotobiotic Pig Model 15 16. Ramesh et al. Vaccines 2019, 7, 777

BWV 302: Norovirus - Malaria We aim to mitigate the global abundance of pathogen mediated digestive tract infections via our novel norovirus/malaria chimeric vaccine. 30

Overview 31 Worldwide estimates each year: Caused by protozoan parasites from the Plasmodium family: • About 219 million cases were reported in 2019 leading to an estimated 409,000 deaths globally. 17 • Approximately 67% of the deaths can be attributed to children. 17 • Direct cost of $12 billion worldwide each year 18 Economic Impact Current Treatment limitations 17,19, 20 • One vaccine currently available for treatment with limited authorization by the EMA in high transmission regions, outside of the of the European Union. • The two most common treatments are Chloroquine phosphate and Artemisinin - based combination (ACT) therapies Norovirus - Malaria 17. WHO, https:// www.who.int /news - room/fact - sheets/detail/malaria 18. https:// www.cdc.gov /malaria/ malaria_worldwide / impact.html 19. . ( https://www.ema.europa.eu/en/news/first - malaria - vaccine - receives - positive - scientific - opinion - ema ) 20. https:// www.nature.com /articles/s41591 - 020 - 1005 - 2.pdf There is growing concern about resistance to mosquito control pesticides and existing malaria treatment. 17, 20

32 Pre - clinical Data: Mouse Model 21 21. BWV Presentation • Vaccination of mice with vaccine candidate P 24 particle presenting the small domain of the CS protein (3D7 - PP) and two controls. Mice were immunized three times with the chimeric nanoparticle using aluminum hydroxide as an adjuvant. Sera was collected and evaluated. • Data demonstrate vaccine candidate produces a higher titer 3D7 - PP 3D7 - His 3D7 - GST Mouse - 1 25600 800 400 Mouse - 2 51200 <100 400 Mouse - 3 25600 400 400 Mouse - 4 25600 <100 800 3D7 - PP 3D7 - His 3D7 - GST Mouse - 1 201400 25600 12800 Mouse - 2 402800 12800 12800 Mouse - 3 201400 25600 12800 Mouse - 4 402800 12800 12800 Antibody titer after 3 nd immunization Antibody titer after 2 nd immunization

33 Pre - clinical Data: Mouse Model 21 21. BWV Presentation based on mouse immunization study conducted by Cincinnati Children’s Hospital Medical Center . VirHRV = virulent human rotavirus IFA of plasmodium sporozoites (3D7) stained with anti - P24 particle presenting the small domain of the CS protein mouse sera 1:4,000 1:1,000 1:2,000 1:8,000 1:16,000 1:32,000 1:4,000 2 nd Ab only, neg - control • The antibodies were also shown to recognize the plasmodium falciparum 3D7 strain using immunofluorescence assays

S&P Platform 1 : • US Patent 8,486,421: “Antigen - Norovirus P - Domain Monomers and Dimers, Antigen - Norovirus P - Particle Molecules, and Methods for Their Making and Use” • US Patent 9,096,644: “Antigen - Norovirus P - Domain Monomers and Dimers, Antigen Norovirus P - Particle Molecules, and Methods for Their Making and Use” • US Patent 9,562,077: ”Protein Complex System For Increased Immunogenicity and Functionality, and Methods Making and Use” • U. S. patent application no. 16/489,095: ”Norovirus S Particle Based Vaccines and Methods of Making and Using Same” • U.S. provisional application nos. 63/149,742 & 63/162,369: ”S60 - HA1 pseudovirus nanoparticles as a new influenza vaccine tactic and candidate” Our U.S. IP Portfolio Influenza 2 : • US Patent 11,123,422: ”Immunogenic composition” • US patent application no. 17/458,712: ”Immunogenic composition” S. pneumonia 3 : • US Patent 9,265,819: “Live, attenuated Streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease” In Process IP 4 : • OUI project 16867 – Influenza A haemagglutinin antigen Group 2 (H3) • OUI Project 16870 – Influenza Group B haemagglutinin antigen • OUI Project 16872 – VLP delivery system for influenza vaccine 34 [1] Cincinnati Children's Hospital Medical Center exclusive license. [2] Oxford University Innovation Limited exclusive licen se. [3] St. Jude Children's Research Hospital, Inc. exclusive license. [4] Oxford University Innovation Limited exclusive licens e.

Initiate IND Enabling studies: • H1Flu • noro - rota 2H2021 mid2022 1H2023 2H2023 1H2022 2H2022 mid2023 Optimization: • H1 Flu • S. pneumo i nduced AOM IND Filing: • H1Flu • noro - rota Phase 1 Completion: • S. pneumo induced AOM Optimization: • H3 & Flu B • nora - rota Initiate IND Enabling; • S. pneumo i nduced AOM IND Filing / Phase 1 Initiation : • S. pneumo induced AOM Phase I Initiation: • H1 Flu • noro - rota Clinical Development Timeline & Milestones 35 * Pipeline projections are based upon the completion of the initial public offering.

36 Investment Highlights ? Lead Vaccine Candidates: Targeting Universal and H1 Influenza utilizing proprietary influenza epitopes of limited variability (ELV) that remain present through viral mutation Esteemed Collaborators: University of Oxford, Cincinnati Children’s, St. Jude’s Children’s POC: Proof - of - Concept IND: Investigational New Drug Application. AOM: acute otitis media ? Opportunistic Business model : Exclusive licenses of assets and platforms, broad business development, opportunistic growth and expansion Broad and diverse vaccine pipeline: Novel preclinical vaccine candidates with near - term POC and IND Proprietary Versatile Vaccine Platform: POC, multi - valent, scalable, and flexible discovery engine with broad therapeutic capabilities We improve the lives of people through discovery and development of novel, transformational and preventive vaccines AOM Prevention Candidate: Targeting S. pneumoniae utilizing a proprietary live - attenuated strain with intranasal delivery